Pharmacist-led care for UTIs: NSW trial evaluation finally out

Lynnette Hoffman

writer

Lynnette Hoffman

Managing Editor

Lynnette Hoffman

Patients say it is convenient, but is it actually helping those who need it most?

Eight out of 10 women who saw a pharmacist to assess and treat their urinary tract infection symptoms reported positive experiences — with many emphasising the high level of convenience, an evaluation of the NSW government sponsored clinical trial into the management of uncomplicated UTIs by community pharmacist has found.

The evaluation by the University of Newcastle was released this week – long after pharmacist prescribing for uncomplicated cystitis became permanent in NSW in 2024.

But while the report is overwhelmingly positive, not everyone is so sure.

RACGP President Dr Michael Wright said the evaluation had failed to provide the necessary clinical outcomes and should not be relied on to develop policy.

“It involved an unrepresentative patient cohort, lacked a clinical control group, and was more focused on measuring the dispensing of medicines rather than whether patients received the healthcare they needed,” Dr Wright said.

“These limitations make the evaluation findings too premature to base policy decisions on.”

Is it really improving access?

Pharmacist prescribing has been promoted as a way to improve access – but despite high levels of satisfaction among participants, uptake has been highest in women with higher socioeconomic status, as well as in urban areas.

“The service was disproportionately used by women with higher levels of education and for those residing in wealthier areas,” the report stated.

Specifically, 38% of participants were in the most advantaged quintile (based on their postcodes), while 9% were from the most disadvantaged quintile.

“The data shows that most patients accessed the service in metropolitan areas (72%), while being employed (80%),” the report also noted.

Participation generally reflected the proportion of pharmacies in a given geographic area. For example, the evaluators note that 14% of pharmacist consultations were in larger rural towns, which house 11% of pharmacies in NSW. But there was limited participation in more remote areas. Only three pharmacies in remote areas provided consultations – and none in very remote areas – although there are 17 pharmacies in remote and very remote areas in NSW.

How effective were the consultations?

The primary outcome of the 10-month trial was self-reported total absence of symptoms within seven days of accessing the service, which was achieved by 79% of nearly 15,000 patients who completed the follow up survey. Partial symptom resolution was reported by another 18%.

According to the report, symptom resolution rates in studies looking at physician-led care range from 67-95%.

In the trial, 93% of patients were prescribed antibiotics.

The rate of adverse events was 5%, with most being gastrointestinal symptoms related to the antibiotics.

The study did not have a comparison group to assess outcomes against usual care.

Dr Wright said the trial helps us understand “how these models operate under tightly governed trial conditions,” but it “does not establish whether these services deliver better outcomes than GP-led care, reduce overall demand for the health system, or do so without compromising patient safety.”

A significant proportion of patients went on to see their GP

Almost one quarter (23%) of patients who saw a pharmacist regarding a UTI saw their GP within seven days– a significantly higher proportion than the 7% who were referred to either their GP or the emergency department by the pharmacist.

In the 28 days after the pharmacy consultation, 43% of patients had seen their GP, according to MBS data analysed as part of the evaluation.

GP consultation rates also increased significantly in the six months following the trial compared to the 12 months prior (15.9 per 100 vs 11.6 per 100).

The reasons for the GP consultation weren’t available, but urine tests were ordered in 49% of GP consults that occurred within 0 to 2 days of the pharmacist consultation, 40% of those within 3 to 6 days, and 19% of those that took place with 7 to 28 days.

“Community pharmacists found the service feasible but emphasised the need for better integration with health systems, including information from pathology services and general practitioners,” the report stated.

For more information

Read the final evaluation report here.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Philip Tong

Dr Philip Tong

Facial Rashes Case Studies – Practical Guide to Assessment and Management

Dr Rupert Hinds

Dr Rupert Hinds

Abdominal Pain in Children – Practical Approach in GP

Prof Roger Chen

Prof Roger Chen

Practical Guide to Improving Control of T2D

A/Prof Debbie Rigby

A/Prof Debbie Rigby

Why Inhaler Device Design and Technique Matters

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Upcoming Healthed Webcast

Tune in for "Gallbladder – When surgery is or is not needed" lecture

Tuesday 26th May, 7pm - 9pm AEST

Speaker

Dr David Yeo

Specialist Upper GI, Hepatobiliary and Bariatric Surgeon; Chris O’Brien Lifehouse, RPA and St George Hospitals

In this talk, surgeon, Dr David Yeo will answer these and many other real-world questions related to this common condition and provide an update on the latest recommendations for the assessment, investigation and management of gallbladder disease.